- Safety Review Committee (SRC) approves single 3mg dose for
the third cohort in Phase 1 trial of PMC-403
DAEJEON, South Korea, July 2, 2024
/PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the
"Company") (KOSDAQ: 208340), a clinical-stage public company
developing next generation therapeutics to treat medical unmet
needs, announced today the decision to advance PMC-403, its
candidate treatment for neovascular age-related macular
degeneration (nAMD), to the fourth single-dose group of 4mg and
first multiple-dose group of 3mg in Phase 1 clinical trial.
PMC-403 is a novel TIE2-activating antibody with the mechanism
of stabilizing pathological and leaky blood vessels. TIE2
receptors, expressed on endothelial cells, are involved in vessel
normalization processes such as angiogenesis and intercellular
adhesion.
This Phase 1 trial targets patients with neovascular age-related
macular degeneration who are no longer responding to anti-VEGF
standard therapeutics. With the SRC's decision, the trial will
advance to the highest single dose cohort (4mg) and the first
multiple ascending dose cohort (3mg), potentially providing more
advanced data from this Phase 1 study.
Dr. Weon Sup Lee, Head of R&D and Chief Technology Officer
at PharmAbcine, stated, "Despite standard anti-VEGF treatments,
many patients with neovascular age-related macular degeneration
continue to experience vision loss and retinal vascular leakage. We
are committed to delivering an innovative new drug with
differentiated mode of action for these patients." He added, "If
final safety is confirmed in this Phase 1 trial, the likelihood of
advancing to Phase 2 will increase, paving the way for the
commercialization of this treatment."
Macular degeneration is a leading cause of blindness caused by
aging-related damage to the retina, particularly due to abnormal
blood vessels in the macula. The global aging population has led to
a rapid increase in macular degeneration cases, and current
standard treatments with anti-VEGF inhibitors are insufficient for
complete treatment. Consequently, there is a growing demand for new
mechanism therapies.
Once PharmAbcine's PMC-403 secures safety at the highest dose
cohort (4mg), it could play a crucial role in treating macular
degeneration. As the likelihood of moving to Phase 2 clinical
trials increases, PMC-403 is expected to provide a new treatment
option for macular degeneration patients worldwide.
About PharmAbcine Inc.
PharmAbcine is a clinical stage public company developing next
generation IgG based therapeutics to treat cancer, neovascular eye
diseases, and vascular related unmet needs.
The Company's main pipeline include clinical assets olinvacimab,
PMC-403, and PMC-309.
Olinvacimab, the Company's lead asset, is ongoing a Phase II
trial in combination with MSD's pembrolizumab for mTNBC patients in
Australia to reconfirm the
encouraging result from Phase Ib olinvacimab plus pembrolizumab
trial, delivering 50% ORR, 67% DCR, and clean safety profile.
PMC-403 is a novel TIE2-activating antibody that stabilizes
dysfunctional leaky disorganized pathological vessels and can be
used for vascular-related eye disease, including wet AMD
(Age-related Macular Degeneration). PMC-403 is currently undergoing
Phase 1 trial for neovascular AMD patients in Korea. PMC-403 is
also being explored to expand into wider therapeutic areas related
to pathological vessels including vessel-related rare diseases and
non-rare diseases.
PMC-309, a novel anti-VISTA-antagonizing IgG in pan pH
conditions, is an immune checkpoint regulator that targets MDSC
(myeloid derived suppressor cells) and M2 macrophages which play
pivotal role in maintaining immunosuppressive TME (Tumor
Microenvironment). Phase I is ongoing at multicenter in
Australia and Phase Ib/II in
combination with MSD's pembrolizumab PMC-309 + Pembrolizumab combo
is in plan.
PMC-005, is an anti-EGFRviii IgG that only binds to EGFRviii
expressed on cancer cells and can be applied to various modalities
including CAR-T, CAR-NK, CAR-Macrophage, T cell/NK cell engager,
and Radio-Immunotherapy.
For additional information about PharmAbcine, visit
http://www.pharmabcine.com or follow on YouTube and
LinkedIn.
For licensing deals, joint venture, co-development, and
collaboration in research or antibody discovery inquiries, please
contact:
Business Development Team
E-mail: bd@pharmabcine.com
Office line: +82 70 4279 5100
For investor relations and public relations inquiries, please
contact:
IR/PR Team
E-mail: pmc_dis@pharmabcine.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pharmabcines-phase-1-clinical-trial-of-pmc-403-for-neovascular-age-related-macular-degeneration-advances-to-both-single-dose-of-4mg-and-multiple-dose-of-3mg-302187664.html
SOURCE PharmAbcine